Hainan Poly Pharm Co (SZSE:300630) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Hainan Poly Pharm Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.29.

Hainan Poly Pharm Co's long-term debt to total assets ratio increased from Sep. 2022 (0.25) to Sep. 2023 (0.29). It may suggest that Hainan Poly Pharm Co is progressively becoming more dependent on debt to grow their business.

Hainan Poly Pharm Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Hainan Poly Pharm Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co LT-Debt-to-Total-Asset Chart

Hainan Poly Pharm Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.06

0.20

0.25

Hainan Poly Pharm Co Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.25	0.25	0.29	0.34	0.29

Hainan Poly Pharm Co LT-Debt-to-Total-Asset Calculation

Hainan Poly Pharm Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	1485.736	/	5959.021
	=	0.25

Hainan Poly Pharm Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	1903.077	/	6687.316
	=	0.28

Hainan Poly Pharm Co (SZSE:300630) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Hainan Poly Pharm Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hainan Poly Pharm Co (SZSE:300630) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051

Website

http://www.hnpoly.com

Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.

Executives

Fan De Zhu	Independent director
Xie Hui Fang	Supervisors
Pu Jian	Executives
Xu Zhao	Securities Affairs Representative
Shen Shi Hua	Executives
Zhou Mao	Directors, Directors, and Executives

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines